Practical Dermatology

11/27/2025

💇‍♀️🧴 WHERE HAIR AND SKIN CARE MEET: Iris Rubin, MD, FAAD, discusses integrative approaches at the intersection of hair care and skin care. This video was recorded at the Science of Skin Summit in Austin, TX. 🩺 👩‍⚕️

📺 Watch here ➡️ https://ow.ly/rUgb50XwiqO

Iris Rubin, MD, FAAD, discusses integrative approaches at the intersection of hair care and skin care. This video was recorded at the Science of...

11/26/2025

🏃💼 ⚖️ BALANCING A BUSY CAREER: Peter A. Lio, MD, a Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine, discusses how he balances his clinical practice with his academic responsibilities, thought leadership, and more in this "Ask Me Anything" mentorship session.

Watch here ➡️ https://ow.ly/zhNC50XwinN

Peter A. Lio, MD, a Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine, discusses...

11/25/2025

📣 🆕 NEW ISSUE ALERT: The November/December issue of Practical Dermatology spotlights GLP-1 Receptor Agonists (GLP-1RAs) and their potential dermatologic and aesthetic applications. Under the guidance of Guest Editor Ted Lain, MD, experts take a comprehensive look from several angles at how these life-changing medications are being studied and applied in dermatology.🩺✨

📚 Featured articles include:
• The Role of GLP-1RAs in Inflammatory Derm – Dr. Michael Payette
• GLP-1RAs and the Aesthetic Patient – Dr. Ardalan Minokadeh
• Pipeline and Potential Roles in Dermatology – Dr. Corey Snyder et al
• Plus More!

Additional highlights:
• Early-use moisturizer in AD prevention
• Managing and screening for hyperhidrosis in pediatric and adult patients
• Practice tips to enhance your digital presence

Read the issue here ➡️ https://ow.ly/n1hm50Xwims

None

11/24/2025

🎙️👨‍⚕️NEW PRACTICAL DERMATOLOGY PODCAST: In the latest episode of the Practical Dermatology Podcast, International Federation of Psoriasis Associations (IFPA) executive director Frida Dunger discusses recent awareness efforts, and Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, is joined by editorial board member Brad P. Glick, DO, MPH, FAAD, for an honest discussion about the state of dermatology residencies. 🔈🩺

Listen here ➡️ https://ow.ly/Ltow50XwhXu

International Federation of Psoriasis Associations (IFPA) executive director Frida Dunger discusses recent awareness efforts, and Practical...

11/22/2025

👩‍⚕️🙋‍♂️🙋‍♀️'ASK ME ANYTHING' MENTORSHIP SESSION: Natasha Atanaskova Mesinkovsa, MD, PhD, vice chair for clinical research in the UC Irvine School of Medicine's Department of Dermatology, discusses how she navigated her unique career path, how she balances her various responsibilities now, and more in this YoungMD Connect "Ask Me Anything" mentorship session.

Watch here ➡️ https://ow.ly/RoC450XwhYh

Natasha Atanaskova Mesinkovsa, MD, PhD, vice chair for clinical research in the UC Irvine School of Medicine's Department of Dermatology, discusses...

11/21/2025

📢 💊 🩺 ORAL MINOXODIL FOR FPHL: Veradermics recently announced the launched the first phase 2/3 clinical trial of an oral treatment for female pattern hair loss (FPHL) with its novel formulation, VDPHL01. Final phase 2 results in both men and women are
expected in 2026.

Read more ➡️ https://ow.ly/1JGx50XuSJT

11/20/2025

🔎 💵 FOLLOWING THE MONEY: A new analysis of National Institutes of Health (NIH) vitiligo funding shows an upward trend, support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and a focus on pathophysiology and treatment development. Medical schools received the most awards.🏅🩺

Read more ➡️ https://ow.ly/ErZT50XuWn8

Funding trends National Institutes of Health (NIH) funding trends shows steady, long-term support for vitiligo research from 1985 through 2024,...

11/19/2025

🔎 📊DRIVEN BY ITCH: A new pre-proof in JAAD shows that both itch and lesion severity independently predict biologic treatment initiation in patients with moderate-to-severe atopic dermatitis (AD).

Read more ➡️ https://ow.ly/hkMZ50Xu7nM

11/18/2025

📰 🩺 NEWS: Arcutis Biotherapeutics, Inc. announced that its supplemental New Drug Application (sNDA) for ZORYVE® ( ) cream 0.3% in children ages 2 to 5 with plaque has been accepted by the FDA. If approved, it would be the first topical PDE4 inhibitor for this age group.

Read more ➡️ https://ow.ly/ji2Z50XtOHp

11/17/2025

📢📊NEW TRALOKINUMAB DATA: Tralokinumab maintained significant efficacy through 32 weeks in adults with moderate-to-severe hand AD in the phase 3b ADHAND trial, addressing what the manufacturer LEO Pharma called one of AD’s most burdensome manifestations.

Read more ➡️ https://ow.ly/V3ZX50Xtbph

LEO Pharma has announced positive 32-week topline results from its ADHAND trial, a phase 3b study evaluating tralokinumab in adults with...

11/16/2025

IMPROVING CARE OPTIONS FOR CTCL: In this episode of C-Suite Chats, Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma and efforts to address those issues.

📺 Watch the episode ➡️ https://ow.ly/c7wc50XrZOf

Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma...

11/14/2025

📢 🧴 The INTEGUMENT-INFANT study of roflumilast cream 0.05% in infants with mild to moderate AD has completed enrollment, according to an announcement from Arcutis. Results are expected in early 2026.

Read more ➡️ https://ow.ly/RCua50XrZ9b